Amanda Jones

Title: Amanda Jones: Innovator in Selective Androgen Receptor Degrader Technologies

Introduction

Amanda Jones is a prominent inventor based in Silver Spring, MI (US). She has made significant contributions to the field of pharmaceuticals, particularly in the development of selective androgen receptor degraders (SARDs). With a total of five patents to her name, her work focuses on innovative solutions for treating various medical conditions.

Latest Patents

One of Amanda's latest patents involves the creation of novel 3-amino propanamide selective androgen receptor degrader (SARD) compounds. This invention provides pharmaceutical compositions and methods for treating prostate cancer, advanced prostate cancer, castration-resistant prostate cancer, androgenic alopecia, and other hyperandrogenic dermal diseases. Additionally, her work addresses conditions such as Kennedy's disease, amyotrophic lateral sclerosis (ALS), and uterine fibroids. The patent also outlines methods for reducing levels of androgen receptor-full length (AR-FL), including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.

Career Highlights

Amanda has worked with notable organizations, including the University of Tennessee Research Foundation and Gtx Corporation. Her experience in these institutions has allowed her to advance her research and contribute to significant innovations in her field.

Collaborations

Some of Amanda's coworkers include Ramesh Narayanan and Duane Douglas Miller. Their collaboration has likely played a role in the success of her projects and patents.

Conclusion

Amanda Jones is a trailblazer in the development of selective androgen receptor degraders, with a focus on addressing critical health issues. Her innovative work continues to impact the pharmaceutical industry positively.